Phase 1 Trial Shows Manageable Safety for CD123 CAR T Cells in Leukemia
A phase 1 clinical trial demonstrated that CD123-directed CAR T-cell therapy is feasible and well-tolerated in patients with relapsed or ...
A phase 1 clinical trial demonstrated that CD123-directed CAR T-cell therapy is feasible and well-tolerated in patients with relapsed or ...
A review in Discover Oncology examines how engineered materials can address manufacturing, delivery, and safety bottlenecks across cellular immunotherapy.
A standardized enzymatic droplet isolation method enables scalable expansion of human dermal papilla cells while preserving key trichogenic signaling pathways ...
The International Society for Stem Cell Research has opened registration and abstract submissions for its 25th anniversary Annual Meeting, to ...
A phase I trial at Ohio State found that CAR T cells engineered to target three B-cell proteins and boosted ...
A Nature Reviews Cancer review argues that metabolism, from CAR design and manufacturing conditions to the patient's diet, is a ...
Researchers have developed engineered feeder cells derived from induced pluripotent stem cells that prolong the survival and boost the killing ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.